Alkem Laboratories Limited, a renowned Indian pharmaceutical company listed on both the BSE (Scrip Code: 539523) and NSE (Symbol: ALKEM), has officially announced the completion of its 100% acquisition of Adroit Biomed Limited, as per the disclosure made on April 23, 2025. This update marks the final step in a strategic acquisition that was initially disclosed in previous communications dated February 7, 2025, and March 28, 2025.

This development was shared with the Corporate Relationship Department of BSE and the National Stock Exchange of India, in compliance with Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, also known as SEBI LODR Regulations.

According to the company’s disclosure, the acquisition has been executed in line with the conditions outlined in the Share Purchase Agreement (SPA) dated March 28, 2025. With this milestone, Adroit Biomed Limited officially becomes a wholly owned subsidiary of Alkem Laboratories, allowing the latter to expand its presence in the nutraceutical and wellness segments, where Adroit has made a notable mark.

Adroit Biomed Limited, an India-based company, is primarily known for its specialty dermatology and wellness products, including skin and hair care solutions enriched with dermatological innovations. The acquisition fits well within Alkem’s strategic focus on diversifying and strengthening its consumer healthcare portfolio, complementing its already strong presence in the pharmaceutical sector.

The completion of the acquisition brings numerous benefits to Alkem Laboratories, such as:

• Expanding market share in the fast-growing nutraceuticals and dermatology segments.

• Strengthening distribution channels through Adroit’s established networks.

• Leveraging brand equity and formulation expertise to enhance future product lines.

As per the SEBI LODR Regulations, a copy of this disclosure will also be uploaded on Alkem’s official website, ensuring transparency and accessibility for stakeholders and investors. The disclosure has been signed and submitted by Mr. Manish Narang, President – Legal, Company Secretary & Compliance Officer of Alkem Laboratories.

Alkem Laboratories’ move to complete this acquisition further underscores its commitment to growth via strategic acquisitions, a strategy that aligns with the evolving demands of both domestic and international markets. The acquisition is also expected to enhance shareholder value and contribute positively to the company’s consolidated financial performance in the upcoming fiscal quarters.

This acquisition is seen as a significant step toward future-ready healthcare solutions, enabling Alkem to enter niche markets with specialized products while continuing its robust performance in core pharmaceutical categories.

In the coming weeks, investors, analysts, and industry observers will likely keep a close watch on Alkem’s integration strategy, product pipeline expansion, and synergies arising out of this acquisition. The company is expected to share further updates as and when required under applicable laws.

The Upcoming IPOs in this week and coming weeks are Ather Energy.

The Current active IPO are Tankup Engineers.

Start your Stock Market Journey and Apply in IPO by Opening Free Demat Account in Choice Broking FinX.

Join our Trading with CA Abhay Telegram Channel for regular Stock Market Trading and Investment Calls by CA Abhay Varn - SEBI Registered Research Analyst.